Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: February 28, 2018

PharmAust receives $354k R&D Tax Incentive Refund

News & Announcements 2018By Richard Hopkins February 28, 2018

180127_R&D Refund

Recent Articles

11 April: Shortfall Placement Oversubscribed
April 11, 2019
Change of Directors’ Interest: Appendix 3Y
March 28, 2019
Phase I Monepantel Tablets Demonstrate High Safety
March 28, 2019
Top 20 Shareholders, March 2019
March 27, 2019

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

PharmAust continues to tick off the milestones at its ongoing Phase I clinical trials for its anti-cancer drug Monepantel in dogs with the escalation study showing no adverse safety issues. https://t.co/DcLgQFpG3U

Reply on Twitter Retweet on Twitter4 Like on Twitter7 Twitter

Copyright © 2019 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions